BoeiK
2021-04-30
Good
Vaccitech prices shares at $17 for U.S. IPO
免责声明：上述内容仅代表发帖人个人观点，不构成本平台的任何投资建议。
分享至
微信
复制链接
精彩评论
我们需要你的真知灼见来填补这片空白
打开APP，发表看法
APP内打开
发表看法
1
1
{"i18n":{"language":"zh_CN"},"detailType":1,"isChannel":false,"data":{"magic":2,"id":103985292,"tweetId":"103985292","gmtCreate":1619743273916,"gmtModify":1634210278133,"author":{"id":3581553267369506,"idStr":"3581553267369506","authorId":3581553267369506,"authorIdStr":"3581553267369506","name":"BoeiK","avatar":"https://static.tigerbbs.com/c5891aad74d41d50786280d6da4d7c64","vip":1,"userType":1,"introduction":"","boolIsFan":false,"boolIsHead":false,"crmLevel":2,"crmLevelSwitch":0,"individualDisplayBadges":[],"fanSize":5,"starInvestorFlag":false},"themes":[],"images":[],"coverImages":[],"extraTitle":"","html":"<html><head></head><body><p>Good</p></body></html>","htmlText":"<html><head></head><body><p>Good</p></body></html>","text":"Good","highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":1,"repostSize":0,"favoriteSize":0,"link":"https://laohu8.com/post/103985292","repostId":2131953739,"repostType":4,"repost":{"id":"2131953739","kind":"highlight","weMediaInfo":{"introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"media_name":"Reuters","id":"1036604489","head_image":"https://static.tigerbbs.com/443ce19704621c837795676028cec868"},"pubTimestamp":1619741712,"share":"https://www.laohu8.com/m/news/2131953739?lang=&edition=full","pubTime":"2021-04-30 08:15","market":"us","language":"en","title":"Vaccitech prices shares at $17 for U.S. IPO","url":"https://stock-news.laohu8.com/highlight/detail?id=2131953739","media":"Reuters","summary":"April 29 (Reuters) - Vaccitech Plc , the biotech startup that owns the technology behind the COVID-1","content":"<p>April 29 (Reuters) - Vaccitech Plc , the biotech startup that owns the technology behind the COVID-19 vaccine developed by Oxford University and <a href=\"https://laohu8.com/S/AZNCF\">AstraZeneca Plc</a>, priced its ordinary shares at $17 each on Thursday ahead of its U.S. initial public offering.</p>\n<p>The British company expects gross proceeds of $110.5 million from the offering of 6.5 mln of its American Depositary Shares (ADSs), representing the same number of ordinary shares. </p>\n<p>Vaccitech had announced its plans to go public earlier this month and said the ADSs would begin trading on the Nasdaq under the symbol \"VACC\" on April 30.</p>\n<p>Its preference for a U.S. listing to one in the UK could further undermine London's attempts to become a major financial hub, particularly after Brexit.</p>\n<p>The company expects the offering to close on May 4.</p>\n<p><a href=\"https://laohu8.com/S/MSTLW\">Morgan Stanley</a>, Jefferies, Barclays and William Blair are acting as bookrunners for the offering. H.C. Wainwright & Co is acting as the lead manager for the offering.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Vaccitech prices shares at $17 for U.S. IPO</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nVaccitech prices shares at $17 for U.S. IPO\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036604489\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/443ce19704621c837795676028cec868);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2021-04-30 08:15</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>April 29 (Reuters) - Vaccitech Plc , the biotech startup that owns the technology behind the COVID-19 vaccine developed by Oxford University and <a href=\"https://laohu8.com/S/AZNCF\">AstraZeneca Plc</a>, priced its ordinary shares at $17 each on Thursday ahead of its U.S. initial public offering.</p>\n<p>The British company expects gross proceeds of $110.5 million from the offering of 6.5 mln of its American Depositary Shares (ADSs), representing the same number of ordinary shares. </p>\n<p>Vaccitech had announced its plans to go public earlier this month and said the ADSs would begin trading on the Nasdaq under the symbol \"VACC\" on April 30.</p>\n<p>Its preference for a U.S. listing to one in the UK could further undermine London's attempts to become a major financial hub, particularly after Brexit.</p>\n<p>The company expects the offering to close on May 4.</p>\n<p><a href=\"https://laohu8.com/S/MSTLW\">Morgan Stanley</a>, Jefferies, Barclays and William Blair are acting as bookrunners for the offering. H.C. Wainwright & Co is acting as the lead manager for the offering.</p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2131953739","content_text":"April 29 (Reuters) - Vaccitech Plc , the biotech startup that owns the technology behind the COVID-19 vaccine developed by Oxford University and AstraZeneca Plc, priced its ordinary shares at $17 each on Thursday ahead of its U.S. initial public offering.\nThe British company expects gross proceeds of $110.5 million from the offering of 6.5 mln of its American Depositary Shares (ADSs), representing the same number of ordinary shares. \nVaccitech had announced its plans to go public earlier this month and said the ADSs would begin trading on the Nasdaq under the symbol \"VACC\" on April 30.\nIts preference for a U.S. listing to one in the UK could further undermine London's attempts to become a major financial hub, particularly after Brexit.\nThe company expects the offering to close on May 4.\nMorgan Stanley, Jefferies, Barclays and William Blair are acting as bookrunners for the offering. H.C. Wainwright & Co is acting as the lead manager for the offering.","news_type":1},"isVote":1,"tweetType":1,"viewCount":125,"commentLimit":10,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"symbols":[],"verified":2,"subType":0,"readableState":1,"langContent":"EN","currentLanguage":"EN","warmUpFlag":false,"orderFlag":false,"shareable":true,"causeOfNotShareable":"","featuresForAnalytics":[],"commentAndTweetFlag":false,"andRepostAutoSelectedFlag":false,"upFlag":false,"length":4,"xxTargetLangEnum":"ORIG"},"commentList":[],"isCommentEnd":true,"isTiger":false,"isWeiXinMini":false,"url":"/m/post/103985292"}
精彩评论